[18F]‐fluorodeoxyglucose‐positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer
- 14 July 2010
- journal article
- clinical trial
- Published by Wiley in Journal of Surgical Oncology
- Vol. 102 (2), 135-140
- https://doi.org/10.1002/jso.21592
Abstract
Background and Objectives Neoadjuvant chemotherapy is applied to improve the prognosis of patients with advanced gastric cancer. However, only a major histopathological response will provide a benefit. Recent studies suggest that [18F]‐fluorodeoxyglucose‐positron‐emission‐tomography (FDG‐PET) correlates with response and survival in patients with gastroesophageal adenocarcinomas undergoing neoadjuvant chemotherapy. We evaluated the potential of FDG‐PET for the assessment of response and prognosis in the multimodality treatment of gastric cancer. Methods Study patients were recruited from a prospective observation trial. Forty two patients with advanced gastric cancer received neoadjuvant chemotherapy and subsequently 40 patients underwent standardized gastrectomy (2 patients with tumor progression had therapy limited to palliative chemotherapy without surgery). Histomorphologic regression was defined as major response when resected specimens contained P = 0.039). No significant correlations between SUV1, SUV2, or SUVΔ% and response or prognosis were found. Conclusion FDG‐PET seems not to be an imaging system that effectively characterizes major/minor response and survival in patients with gastric cancer following multimodality treatment. J. Surg. Oncol. 2010;102:135–140.Keywords
This publication has 18 references indexed in Scilit:
- European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancerEuropean Journal Of Cancer, 2008
- Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective StudyClinical Cancer Research, 2008
- The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximabGastric Cancer, 2007
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal CancerAnnals of Surgery, 2005
- Regression von Ösophaguskarzinomen nach neoadjuvanter RadiochemotherapieDer Pathologe, 2004
- Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective TrialJournal of Clinical Oncology, 2003
- Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II studyGastric Cancer, 2003
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958